OXFORD, England – U-Ploid Biotechnologies has announced the launch of its innovative platform designed to improve egg cell quality, a critical determinant in IVF success, addressing the unmet need for age-related infertility treatments. The company's technology aims to repair decades of damage accumulated by eggs, a novel approach that aims to improve the viability of older eggs within an IVF cycle.
Addressing Age-Related Fertility Decline
Age-related female fertility decline affects millions, placing emotional and financial strain on families undergoing multiple failed IVF cycles. U-Ploid is dedicated to transforming the lives of those affected by developing a therapy that increases the likelihood for older eggs to support viable pregnancies.
"Our team is developing technology that directly targets the root cause of age-related female infertility," said Dr. Chloe Charalambous, Co-founder & COO of U-Ploid Biotechnologies. "By improving the health of older eggs, we have the opportunity to help millions of people in their fertility journey."
Novel Approach to Improve Egg Viability
U-Ploid’s proprietary technology aims to improve the viability of older eggs within an IVF cycle. The company is dedicated to collaborating with leading fertility clinics to bring this transformative technology to patients. Clinical studies are being prepared to validate the efficacy and safety of its platform and is committed to obtaining regulatory approvals for widespread adoption.
The Vision for the Future
"We are thrilled to introduce U-Ploid’s breakthrough technology, a significant step forward in addressing the global challenge of age-related infertility," said Dr. Jordan Abdi, Co-founder & CEO. "By improving egg quality, we aim to dramatically increase the propensity for successful pregnancies through IVF."
